Company news

Sareum Holdings plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sierra seeks strategic options for SRA737

June 27, 2019

Placing to progress TYK2/JAK1 programmes

June 25, 2019

Portfolio Update

June 13, 2019

Key takeaways from SRA737 webcast at ASCO

June 3, 2019

Positive SRA737 data presented at ASCO

June 3, 2019

ASCO abstracts for SRA737 published

May 16, 2019

Sareum notes Sierra Oncology Q1 2019 Results

May 8, 2019

Sareum to Present at BioTrinity 2019 in London

April 30, 2019

SRA737 Phase I/IIa data to be presented at ASCO

April 23, 2019

Preclinical Data for SRA737 Presented at AACR 2019

April 2, 2019

Sareum Holdings PLC Issue of Options

March 12, 2019

Half-yearly results ended 31 December 2018

March 4, 2019

Sierra Oncology has reported its 2018 Results

February 28, 2019

New SRA737 preclin data to be presented at AACR

February 28, 2019

Sierra Oncology to present SRA737 at DDR Tx Summit

January 23, 2019

Amendment to Preclinical Efficacy Announcement

November 30, 2018

Preclinical Efficacy for Immunotherapy Combination

November 30, 2018

Preclinical Data for SRA737 in Ovarian Cancer

November 15, 2018

AGM NOTICE

November 14, 2018

Directorate Change

November 13, 2018

Sierra Oncology Q3 2018 Results

November 8, 2018

Completion of Placing

October 26, 2018

Final results for the year ended 30 June 2018

October 1, 2018

Notice of Results

September 27, 2018

TYK2/JAK1 selected for certain cancers

September 26, 2018

Pre-Close Trading Statement

September 11, 2018

Selection of TYK2/JAK1 for autoimmune diseases

September 10, 2018

Sareum notes Sierra Oncology Q2 2018 Results

August 9, 2018

Notification of PCA Shareholding

July 11, 2018

Advisers

June 15, 2018

Sareum regains rights to Aurora+FLT3 inhibitors

May 31, 2018

SRA737 trial update in Sierra Oncology Q1 Results

May 10, 2018

Sareum to Present at BioTrinity 2018 in London

April 24, 2018

AACR 2018 Update

April 17, 2018

Late-breaker abstract for SRA737 accepted for AACR

March 15, 2018

Interim Results

March 13, 2018

Sierra Oncology expands SRA737 development program

February 27, 2018

Preclinical synergy of sra737 and PARP inhibitor

February 22, 2018

Notice of Interim Results

February 13, 2018

Issue of Options

December 20, 2017

Patent Grants in Japan & China for TYK2 Inhibitors

December 19, 2017

Notice of AGM and Annual Report & Accounts

November 20, 2017

Placing

November 14, 2017

Sierra Reports Preclinical Data for Chk1 Inhibitor

October 31, 2017

Sierra Oncology host KOL Meeting on 12 Oct in NY

October 9, 2017

Sierra Oncology to host call on Chk1 inhibitor

September 18, 2017

Sareum to Present at the ICCS 2017

June 19, 2017

Chk1 Clinical Trials Update

June 5, 2017

Sierra Oncology Granted US and EU Patents

May 31, 2017

Sierra Oncology to Present at ASCO Annual Meeting

May 25, 2017

← Newer news releases · Older news releases →

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.